These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 28321057

  • 1. The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes.
    Kodera R, Shikata K, Nakamura A, Okazaki S, Nagase R, Nakatou T, Haisa S, Hida K, Miyashita K, Makino H.
    Intern Med; 2017; 56(6):605-613. PubMed ID: 28321057
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Distinct glucose-lowering properties in good responders treated with sitagliptin and alogliptin.
    Kutoh E, Hirate M, Wada A.
    Int J Clin Pract; 2015 Nov; 69(11):1296-302. PubMed ID: 26194442
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Rhee EJ, Lee WY, Min KW, Shivane VK, Sosale AR, Jang HC, Chung CH, Nam-Goong IS, Kim JA, Kim SW, Gemigliptin Study 006 Group.
    Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.
    Umezawa S, Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y, Minagawa F, Obana M, Iemitsu K, Ito S, Amamiya H, Kaneshiro M, Takai M, Kaneshige H, Hoshino K, Ishikawa M, Minami N, Takuma T, Sasai N, Aoyagi S, Kawata T, Mokubo A, Miyairi Y, Takeda H, Honda S, Machimura H, Motomiya T, Waseda M, Naka Y, Tanaka Y, Terauchi Y, Matsuba I.
    BMC Endocr Disord; 2015 Jul 03; 15():34. PubMed ID: 26137940
    [Abstract] [Full Text] [Related]

  • 9. Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
    Kutoh E, Wada A, Terayama S.
    Clin Drug Investig; 2016 Oct 03; 36(10):809-18. PubMed ID: 27352309
    [Abstract] [Full Text] [Related]

  • 10. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
    Kim HS, Shin JA, Lee SH, Kim ES, Cho JH, Son HY, Yoon KH.
    Diabetes Technol Ther; 2013 Oct 03; 15(10):810-6. PubMed ID: 24050737
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes.
    Kusunoki M, Sato D, Nakamura T, Oshida Y, Tsutsui H, Natsume Y, Tsutsumi K, Miyata T.
    Drug Res (Stuttg); 2016 Jan 03; 66(1):18-22. PubMed ID: 26125284
    [Abstract] [Full Text] [Related]

  • 13. Factors associated with the glucose-lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials.
    Tajima N, Eiki JI, Okamoto T, Okuyama K, Kawashima M, Engel SS.
    J Diabetes Investig; 2020 May 03; 11(3):640-646. PubMed ID: 31743602
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Roussel R, Duran-García S, Zhang Y, Shah S, Darmiento C, Shankar RR, Golm GT, Lam RLH, O'Neill EA, Gantz I, Kaufman KD, Engel SS.
    Diabetes Obes Metab; 2019 Apr 03; 21(4):781-790. PubMed ID: 30393950
    [Abstract] [Full Text] [Related]

  • 19. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.
    Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I, ASSET-K Study group.
    Diabetes Res Clin Pract; 2012 Jan 03; 95(1):e20-2. PubMed ID: 22055835
    [Abstract] [Full Text] [Related]

  • 20. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
    Thayer S, Chow W, Korrer S, Aguilar R.
    Curr Med Res Opin; 2016 Jun 03; 32(6):1087-96. PubMed ID: 26938635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.